ASX-listed diagnostics innovator Proteomics International Laboratories plans to start a commercial roll-out of its groundbreaking, simple “traffic light” diagnostic blood test for endometriosis within months, in the process revolutionising healthcare for the disease.
The company says its latest trial of its PromarkerEndo test has put it on a fast track to deliver the first clinically viable, real-world, non-invasive diagnostic test for a disease affecting one in nine women and girls and costing the Australian economy nearly $10 billion.
